Gil Serrancolí

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 6

Top Topics

Top Venues

Communications medicine

International journal for numerical methods in biomedical engineering

International journal of molecular sciences

Medicina (Kaunas, Lithuania)

This page only lists publications with an associated author ORCID identifier.

Publications

Lidia Rueda-Galindo, María Fernanda Zerón-Rugerio, Antonio J Sánchez Egea, Gil Serrancolí, María Fernanda Zerón-Rugerio
A Mediterranean-Style Diet Plan Is Associated with Greater Effectiveness and Sustainability in Weight Loss in Patients with Obesity after Endoscopic Bariatric Therapy. Medicina (Kaunas, Lithuania) 58 (2) (2022)
Alisdair R MacLeod, Nicholas Peckham, Gil Serrancolí, Ines Rombach, Patrick Hourigan, Vipul I Mandalia, Andrew D Toms, Benjamin J Fregly, Harinderjit Singh Gill
Personalised high tibial osteotomy has mechanical safety equivalent to generic device in a case-control in silico clinical trial. Communications medicine 1 (1) (2021)
Marta Manzano, Gil Serrancolí
A factorization-based algorithm to predict EMG data using only kinematics information. International journal for numerical methods in biomedical engineering 37 (7) (2021)
Gil Serrancolí, Cristiano Alessandro, Matthew C Tresch
The Effects of Mechanical Scale on Neural Control and the Regulation of Joint Stability. International journal of molecular sciences 22 (4) (2021)
Alisdair R MacLeod, Nicholas Peckham, Gil Serrancolí, Ines Rombach, Patrick Hourigan, Vipul I Mandalia, Andrew D Toms, Benjamin J Fregly, Harinderjit Singh Gill
Personalised high tibial osteotomy has mechanical safety equivalent to generic device in a case-control in silico clinical trial. Communications medicine 1 (1) (2021)
Alisdair R MacLeod, Nicholas Peckham, Gil Serrancolí, Ines Rombach, Patrick Hourigan, Vipul I Mandalia, Andrew D Toms, Benjamin J Fregly, Harinderjit Singh Gill
Personalised high tibial osteotomy has mechanical safety equivalent to generic device in a case-control in silico clinical trial. Communications medicine 1 (2021)